https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-02-16 / Genes Immun 2022 Feb;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-02-16 / Genes Immun 2022 Feb;2022-02-16 00:00:002022-02-21 07:49:56Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-04 / Cancer Immunol Immunother 2021 Jul;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-04 / Cancer Immunol Immunother 2021 Jul;2021-07-04 00:00:002021-11-15 12:29:15Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-02-25 / Neuro Oncol 2021 02;23(2):240-250
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-02-25 / Neuro Oncol 2021 02;23(2):240-2502021-02-25 00:00:002021-11-15 19:08:36DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-12-30 / DNA Repair (Amst) 2020 Dec;98:103037
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-12-30 / DNA Repair (Amst) 2020 Dec;98:1030372020-12-30 00:00:002021-11-15 13:16:40Impaired DNA repair in mouse monocytes compared to macrophages and precursors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-12-24 / Cancers (Basel) 2020 Dec;13(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-12-24 / Cancers (Basel) 2020 Dec;13(1)2020-12-24 00:00:002021-11-15 13:17:14Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-11-22 / Biomedicines 2020 Nov;8(11)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-11-22 / Biomedicines 2020 Nov;8(11)2020-11-22 00:00:002021-11-15 19:49:33Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-23 / Biomedicines 2020 Jul;8(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-23 / Biomedicines 2020 Jul;8(8)2020-07-23 00:00:002021-11-15 19:51:32Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-6462020-06-30 00:00:002021-11-15 13:19:48Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2020-06-02 12:45:162020-06-02 13:07:50IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-19 / Medicines (Basel) 2020 May;7(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
